Answers are grounded in this paper and cite their sources.
HIV-positive TB co-infected patients are at increased risk of multidrug-resistant (MDR)-TB compared to HIV-negative patients. Co-treatment of MDR-TB and HIV is common particularly in Sub-Saharan Africa where the co-morbidity is endemic. We discuss potential cellular metabolic pathway-mediated drug-drug interactions and the possible effect on HIV treatment outcomes of commonly prescribed antiretroviral therapy.
No takes yet. Share an insight, caveat, or question.
Mukonzo et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: